Volume 28, Number 9—September 2022
CME ACTIVITY - Research
Increasing Incidence of Invasive Group A Streptococcus Disease, Idaho, USA, 2008–2019
Table 3
Type of infection or clinical syndrome | No. (%) patients |
p value‡ | ||
---|---|---|---|---|
Overall, N = 476† | 2008–2013, n = 82† | 2014–2019, n = 394 | ||
Bacteremia without focus§ | 163 (34.2) | 34 (41.5) | 129 (32.7) | 0.13 |
Cellulitis | 197 (41.4) | 30 (36.6) | 167 (42.4) | 0.33 |
Pneumonia | 80 (16.8) | 15 (18.3) | 65 (16.5) | 0.69 |
Streptococcal toxic shock syndrome | 25 (5.3) | 0 (0.0) | 25 (6.4) | 0.02 |
Septic arthritis | 24 (5.0) | 6 (7.3) | 18 (4.6) | 0.30 |
Empyema | 19 (4.0) | 4 (4.9) | 15 (3.8) | 0.65 |
Necrotizing fasciitis | 12 (2.5) | 4 (4.9) | 8 (2.0) | 0.14 |
Osteomyelitis | 6 (1.3) | 0 (0.0) | 6 (1.5) | 0.26 |
Meningitis | 4 (0.8) | 0 (0.0) | 4 (1.0) | 0.36 |
Other¶ | 3 (0.6) | 1 (1.2) | 2 (0.5) | 0.46 |
*Cases can have >1 type of infection or clinical syndrome. †Excludes 7 cases with missing data on type of infection or clinical syndrome, all during 2008–2013. ‡By χ2 test. §Group A Streptococcus isolated from blood, with no other clinical syndrome identified. ¶Other includes abscess, epiglottitis, and pelvic inflammatory disease.
Page created: July 15, 2022
Page updated: August 22, 2022
Page reviewed: August 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.